Accelerating Ovarian Age: Cancer Treatment in the Premenopausal Woman

 

 Permissions and Reprints

Abstract

The reproductive sequelae of cancer treatments may provide an important model of accelerated ovarian aging. Tens of thousands of women treated for cancer each year experience infertility and early menopause as a result of treatment. A spectrum of reproductive compromise commonly ranges from immediate menopause at the time of cancer treatment to the less proximate outcome of early menopause in the years to decades after treatment. A woman's reproductive lifespan can be shortened after chemotherapy or radiation because such treatments likely decrease the number of viable eggs after treatment. This acceleration in the decline of the number of follicles leads to increased rates of not only infertility and miscarriage but also early menopause, which represents the most extreme form of accelerated ovarian aging. The degree of reproductive impairment is dependent on chronologic age and the diagnosis or treatment. The variation in outcomes that persist may be partially explained by pretreatment ovarian reserve. Establishing the use of clinical predictors such as ovarian reserve markers to effectively anticipate such outcomes is an obvious and important keystone in the foundation of cancer survivorship research. An improved understanding of cancer treatment's ability to accelerate follicle death, decrease fecundability, and initiate an earlier menopause could provide a clinically relevant, time-shortened, and reproducible snapshot into the basic biology of ovarian aging.

• References

• 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1) 11-30
  CrossrefPubMedGoogle Scholar
• 2 Siegel R, DeSantis C, Virgo K , et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62 (4) 220-241
  CrossrefPubMedGoogle Scholar
• 3 Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14 (5) 1718-1729
  PubMedGoogle Scholar
• 4 Chemaitilly W, Mertens AC, Mitby P , et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006; 91 (5) 1723-1728
  CrossrefPubMedGoogle Scholar
• 5 Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289 (22) 1159-1162
  CrossrefPubMedGoogle Scholar
• 6 Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000; 169 (1-2) 123-131
  CrossrefPubMedGoogle Scholar
• 7 Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 2006; 11 (2) 96-110
  CrossrefPubMedGoogle Scholar
• 8 Letourneau JM, Ebbel EE, Katz PP , et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2012; 118 (6) 1710-1717
  CrossrefPubMedGoogle Scholar
• 9 Patel A, Sreedevi M, Malapati R , et al. Reproductive health assessment for women with cancer: a pilot study. Am J Obstet Gynecol 2009; 201 (2) e1-e4
  PubMedGoogle Scholar
• 10 Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update 2009; 15 (5) 587-597
  CrossrefPubMedGoogle Scholar
• 11 Carter J, Rowland K, Chi D , et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol 2005; 97 (1) 90-95
  CrossrefPubMedGoogle Scholar
• 12 Wallace WHB. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer 2011; 117 (10, Suppl): 2301-2310
  CrossrefPubMedGoogle Scholar
• 13 Anderson RA, Wallace WHB. Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril 2013; 99 (6) 1469-1475
  CrossrefPubMedGoogle Scholar
• 14 Lee SJ, Schover LR, Partridge AH , et al; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24 (18) 2917-2931
  CrossrefPubMedGoogle Scholar
• 15 Rugo HS, Rosen MP. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA 2011; 306 (3) 312-314
  CrossrefPubMedGoogle Scholar
• 16 Schover LR. Patient attitudes toward fertility preservation. Pediatr Blood Cancer 2009; 53 (2) 281-284
  CrossrefPubMedGoogle Scholar
• 17 Albright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature: report of 11 cases with a digression on hormonal control of axillary and pubic hair. Am J Med Sci 1942; 204: 625-648
  CrossrefPubMedGoogle Scholar
• 18 Letourneau JM, Melisko ME, Cedars MI, Rosen MP. A changing perspective: improving access to fertility preservation. Nat Rev Clin Oncol 2011; 8 (1) 56-60
  CrossrefPubMedGoogle Scholar
• 19 Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360 (6) 606-614
  CrossrefPubMedGoogle Scholar
• 20 Chemaitilly W, Mertens AC, Mitby P , et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006; 91 (5) 1723-1728
  CrossrefPubMedGoogle Scholar
• 21 Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary?. Hum Reprod Update 2012; 18 (5) 525-535
  CrossrefPubMedGoogle Scholar
• 22 Letourneau JM, Ebbel EE, Katz PP , et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 2012; 118 (7) 1933-1939
  CrossrefPubMedGoogle Scholar
• 23 Sklar CA, Mertens AC, Mitby P , et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98 (13) 890-896
  CrossrefPubMedGoogle Scholar
• 24 Rosen MP, Sternfeld B, Schuh-Huerta SM, Reijo Pera RA, McCulloch CE, Cedars MI. Antral follicle count: absence of significant midlife decline. Fertil Steril 2010; 94 (6) 2182-2185
  CrossrefPubMedGoogle Scholar
• 25 Rosen MP, Johnstone E, Addauan-Andersen C, Cedars MI. A lower antral follicle count is associated with infertility. Fertil Steril 2011; 95 (6) 1950-1954 , e1
  CrossrefPubMedGoogle Scholar
• 26 Levi AJ, Raynault MF, Bergh PA, Drews MR, Miller BT, Scott Jr RT. Reproductive outcome in patients with diminished ovarian reserve. Fertil Steril 2001; 76 (4) 666-669
  CrossrefPubMedGoogle Scholar
• 27 Elter K, Kavak ZN, Gokaslan H, Pekin T. Antral follicle assessment after down-regulation may be a useful tool for predicting pregnancy loss in in vitro fertilization pregnancies. Gynecol Endocrinol 2005; 21 (1) 33-37
  CrossrefPubMedGoogle Scholar
• 28 Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 2010; 94 (1) 156-166
  CrossrefPubMedGoogle Scholar
• 29 Letourneau JM, Niemasik EE, McCulloch CE , et al. Temporary amenorrhea predicts future infertility in young women treated with chemotherapy. Journal of Cancer Theraputics & Research 2013; 2: 1-9
  PubMedGoogle Scholar
• 30 Petrek JA, Naughton MJ, Case LD , et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24 (7) 1045-1051
  CrossrefPubMedGoogle Scholar
• 31 Sukumvanich P, Case LD, Van Zee K , et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010; 116 (13) 3102-3111
  CrossrefPubMedGoogle Scholar
• 32 Kiserud CE, Fosså A, Holte H, Fosså SD. Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer 2007; 96 (9) 1442-1449
  PubMedGoogle Scholar
• 33 Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril 2010; 94 (5) 1652-1656
  CrossrefPubMedGoogle Scholar
• 34 Loprinzi CL, Wolf SL, Barton DL, Laack NN. Symptom management in premenopausal patients with breast cancer. Lancet Oncol 2008; 9 (10) 993-1001
  CrossrefPubMedGoogle Scholar
• 35 Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004; 10 (3) 251-266
  CrossrefPubMedGoogle Scholar
• 36 Amir E, Freedman O, Allen L, Colgan T, Clemons M. Defining ovarian failure in amenorrheic young breast cancer patients. Breast 2010; 19 (6) 545-548
  CrossrefPubMedGoogle Scholar
• 37 Di Cosimo S, Alimonti A, Ferretti G , et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 2004; 15 (7) 1065-1071
  CrossrefPubMedGoogle Scholar
• 38 Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007; 43 (11) 1646-1653
  CrossrefPubMedGoogle Scholar
• 39 Luciano AM, Franciosi F, Lodde V , et al. Oocytes isolated from dairy cows with reduced ovarian reserve have a high frequency of aneuploidy and alterations in the localization of progesterone receptor membrane component 1 and aurora kinase B. Biol Reprod 2013; 88 (3) 58
  CrossrefPubMedGoogle Scholar
• 40 Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic markers of ovarian follicle number and menopause in women of multiple ethnicities. Hum Genet 2012; 131 (11) 1709-1724
  CrossrefPubMedGoogle Scholar
• 41 van Dorp W, van den Heuvel-Eibrink MM, Stolk L , et al. Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum Reprod 2013; 28 (4) 1069-1076
  CrossrefPubMedGoogle Scholar
• 42 De Vos M, Devroey P, Fauser BCJM. Primary ovarian insufficiency. Lancet 2010; 376 (9744) 911-921
  CrossrefPubMedGoogle Scholar
• 43 Anderson RA, Cameron DA. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96 (5) 1336-1343
  CrossrefPubMedGoogle Scholar
• 44 Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010; 20 (2) 280-285
  CrossrefPubMedGoogle Scholar
• 45 Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012; 97 (6) 2059-2067
  CrossrefPubMedGoogle Scholar
• 46 Gracia CR, Sammel MD, Freeman E , et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012; 97 (1) 134-140 , e1
  CrossrefPubMedGoogle Scholar
• 47 Grynnerup AG-A, Lindhard A, Sørensen S. The role of anti-Müllerian hormone in female fertility and infertility - an overview. Acta Obstet Gynecol Scand 2012; 91 (11) 1252-1260
  CrossrefPubMedGoogle Scholar
• 48 Kevenaar ME, Meerasahib MF, Kramer P , et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006; 147 (7) 3228-3234
  CrossrefPubMedGoogle Scholar
• 49 Appt SE, Clarkson TB, Chen H , et al. Serum antimüllerian hormone predicts ovarian reserve in a monkey model. Menopause 2009; 16 (3) 597-601
  CrossrefPubMedGoogle Scholar
• 50 Velentgas P, Daling JR, Malone KE , et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 1999; 85 (11) 2424-2432
  CrossrefPubMedGoogle Scholar
• 51 Rippy EE, Karat IF, Kissin MW. Pregnancy after breast cancer: the importance of active counselling and planning. Breast 2009; 18 (6) 345-350
  CrossrefPubMedGoogle Scholar
• 52 Overbeek A, van den Berg MH, Kremer LC , et al; DCOG LATER-VEVO study group. A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. BMC Cancer 2012; 12: 363
  CrossrefPubMedGoogle Scholar
• 53 Reulen RC, Zeegers MP, Wallace WH , et al; British Childhood Cancer Survivor Study. Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 2009; 18 (8) 2239-2247
  CrossrefPubMedGoogle Scholar
• 54 Blakely LJ, Buzdar AU, Lozada JA , et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004; 100 (3) 465-469
  CrossrefPubMedGoogle Scholar
• 55 Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002; 20 (7) 1880-1889
  CrossrefPubMedGoogle Scholar
• 56 Schover LR. Motivation for parenthood after cancer: a review. J Natl Cancer Inst Monogr 2005; 2005 (34) 2-5
  CrossrefPubMedGoogle Scholar
• 57 Niemasik EE, Letourneau J, Dohan D , et al. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv 2012; 6 (3) 324-332
  CrossrefPubMedGoogle Scholar
• 58 Behringer K, Breuer K, Reineke T , et al; German Hodgkin's Lymphoma Study Group. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23 (30) 7555-7564
  CrossrefPubMedGoogle Scholar
• 59 Anderson RA, Themmen APN, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006; 21 (10) 2583-2592
  CrossrefPubMedGoogle Scholar
• 60 Tham Y-L, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007; 30 (2) 126-132
  CrossrefPubMedGoogle Scholar
• 61 Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983; 52 (6) 988-993
  CrossrefPubMedGoogle Scholar
• 62 TeVelde E, Pearson P. The variability of female reproductive ageing. Hum Reprod Update 2002; 8 (2) 141-154
  CrossrefPubMedGoogle Scholar
• 63 Decanter C, Morschnauser F, Pigny P , et al. Anti-mullerian hormone follow-up in young women treated by chemotherapy for lymphoma preliminary results. Reprod Biomed Online 2010; 20 (2) 280-285
  CrossrefPubMedGoogle Scholar
• 64 Garcia C, Samuel M, Freeman E , et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012; 97 (1) 134-140. e1
  CrossrefPubMedGoogle Scholar